AGTC APPLIED GENETIC TECHNOLOGIES

AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021

AGTC to Present at the OIS Gene Therapy Innovation Showcase on February 18, 2021

GAINESVILLE, Fla. and CAMBRIDGE, Mass., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that Sue Washer, President & Chief Executive Officer, will participate at the OIS Gene Therapy Innovation Showcase, taking place virtually on Thursday, February 18, 2021 from 12:00 PM to 3:00 PM CST.

The event will include a market overview and start-up spotlight, followed by a panel discussion featuring recognized experts in the field. The panel will highlight unique perspectives on gene therapy in the eye care sector and product viability.

Event registration is complimentary. To register, visit:

About AGTC

AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.

IR/PR Contacts:

David Carey (IR) or Tom Vickery (PR)

FINN Partners

T: (212) 867-1768 or (646) 871-8482

 or 

Corporate Contacts:

Bill Sullivan

Chief Financial Officer

Applied Genetic Technologies Corporation

T: (617) 843-5728

Stephen Potter

Chief Business Officer

Applied Genetic Technologies Corporation

T: (617) 413-2754



EN
16/02/2021

Underlying

AGTCAPPLIED GENETIC TECHNOLOGIES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on APPLIED GENETIC TECHNOLOGIES

 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

Syncona Limited Portfolio Company Successfully Completes Tender Offer ...

Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation GAINESVILLE, Fla. and CAMBRIDGE, Mass., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today the successful completion of the previously announced tender offer (the “Offer”) to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”). The Offer, as extended, expired at 5:00 p.m., Eastern Time, on Nove...

December 1, 2022 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Appl...

Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (“AGTC” or the “Company”) (Nasdaq: AGTC), announced today that a portfolio company of Syncona Limited (LON: SYNC) (“Syncona”) has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to con...

November 29, 2022 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by Nov...

*FINAL REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *FINAL REMINDER* GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement ...

November 28, 2022 1 EN
David Nierengarten ... (+2)
  • David Nierengarten
  • Dennis Pak
AGTC APPLIED GENETIC TECHNOLOGIES
11/25/22 November 25, 2022 1 EN
 PRESS RELEASE
Free
AGTC APPLIED GENETIC...

*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November ...

*REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER* GAINESVILLE, Fla. and CAMBRIDGE, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders: A Syncona Limited portfolio company has commenced a tender offer to purchase all outstanding shares of AGTC common stock at a price per share of $0.34 in cash plus the right for AGTC stockholders to receive additional aggregate payments of up to $0.73 per share upon the achievement of specifi...

November 22, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch